GL1X · GenesisL1 explorer

MolNFT v1 · #165336 · protein

Crystal structure of HLA A2*01-avydgrehtv

6TRN · MHC class I antigen: “Crystal structure of HLA A2*01-avydgrehtv”. X-ray diffraction, 6 pockets (best druggability 0.69). MolNFT v1 #165336 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
6TRN
Type
protein
Length
382 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
MHC class I antigen; Beta-2-microglobulin; Mage-A4 peptide (amino acids 230-239) variant
UniProt
A0A5B8RNS7, P61769
Pockets
6 · best druggability 0.69

Structure

x-ray diffraction · 3 distinct chains · 19% helix, 42% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMHC class I antigenprotein27427% helix, 40% strandA0A5B8RNS7
BBeta-2-microglobulinprotein980% helix, 50% strandP61769
CMage-A4 peptide (amino acids 230-239) variantprotein100% helix, 0% strand—

Ligands and binding sites

  • EDO · 1,2-ethanediol · additive · 3 copies · chains A, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15970.690.7854empty
2670.450.8318empty
3940.430.7917empty
4590.350.7815empty
5870.320.7418empty

Interfaces

2 interfaces between chains.

  • A–B · 1228 Ų buried · 18 hydrogen bonds · protein-protein
  • A–C · 890 Ų buried · 17 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 6TRN · Crystal structure of HLA A2*01-AVYDGREHTV · the same entry in another collection · chain A against A, TM-score 1.00
  • P61769 · AlphaFold monomer V2.0 prediction for beta-2-microglobulin (P61769) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.